Pancreatic Cancer Research

ResearcherRevolution Medicines (United States)Active in the last 2 years

Ida Aronchik

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0002-1590-8778; OpenAlex author ID A5078668389. Sources: OpenAlex.

Their work

Papers
1
Trials
0
Grants
0
Labs led
0
Collaborators
14
Papers, trials and grants by year

2026: 1 paper

Papers 1

  1. Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer. Co-author DOI 10.1038/s41591-026-04537-w↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alexander Starodub · 1 shared paper, 2026 · strength 0.18
  2. Ashenafi Shiferaw Bulle · 1 shared paper, 2026 · strength 0.18
  3. Julien Dilly · 1 shared paper, 2026 · strength 0.18
  4. Wungki Park · 1 shared paper, 2026 · strength 0.18
  5. Urszula N. Wasko · 1 shared paper, 2026 · strength 0.18
  6. Andrew J. Aguirre · 1 shared paper, 2026 · strength 0.18
  7. Kian‐Huat Lim · 1 shared paper, 2026 · strength 0.18
  8. Brian Matthew Wolpin · 1 shared paper, 2026 · strength 0.18
  9. Anirban Maitra · 1 shared paper, 2026 · strength 0.18
  10. Minal A. Barve · 1 shared paper, 2026 · strength 0.18
  11. David S. Hong · 1 shared paper, 2026 · strength 0.18
  12. Ignacio Garrido‐Laguna · 1 shared paper, 2026 · strength 0.18
  13. Mallika Singh · 1 shared paper, 2026 · strength 0.18
  14. Alexander I. Spira · 1 shared paper, 2026 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.